Circulating immune checkpoints predict heart failure outcomes

Circulating immune checkpoints predict heart failure outcomes

Abstract Aims There are limited data examining the role of immune checkpoint (IC) ligands in the pathophysiology of heart failure (HF). Therefore, we explore this in three HF animal models and in three different human cohorts (healthy, stable, and worsening HF). Methods and results Transcriptomic an...

Полное описание

Библиографические подробности
Главные авторы:	Elles M. Screever, Laura I.E. Yousif, Javid J. Moslehi, Joe‐Elie Salem, Adriaan A. Voors, Herman H.W. Silljé, Rudolf A. deBoer, Wouter C. Meijers
Формат:	Статья
Язык:	English
Опубликовано:	Wiley 2023-08-01
Серии:	ESC Heart Failure
Предметы:	Immune checkpoints PD‐L1 PD‐L2 Galectin‐9 Heart failure
Online-ссылка:	https://doi.org/10.1002/ehf2.14304

Схожие документы

Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study
по: Douglas B. Johnson, и др.
Опубликовано: (2019-05-01)

Checkpoint Inhibition in Myeloma: Opportunities and Challenges
по: Federica Costa, и др.
Опубликовано: (2018-09-01)

The role of immune checkpoints in cardiovascular disease
по: Laura I. Yousif, и др.
Опубликовано: (2022-10-01)

Enhancing cancer care with improved checkpoint inhibitors
по: Vickram A S, и др.
Опубликовано: (2024-10-01)

Checkmate with checkpoint inhibitors: New paradigm in immunotherapy
по: Ruby Dhar, и др.
Опубликовано: (2023-04-01)

Characterization of PD-1/PD-L1 Immune Checkpoint Expression in Osteosarcoma
по: Kazuhiko Hashimoto, и др.
Опубликовано: (2020-07-01)

Immune Checkpoint in Glioblastoma: Promising and Challenging
по: Jing Huang, и др.
Опубликовано: (2017-05-01)

Phytochemicals in Cancer Immune Checkpoint Inhibitor Therapy
по: Juwon Lee, и др.
Опубликовано: (2021-07-01)

Overview of the Cardiotoxicity Induced by PD-1/PD-L1 Immune Checkpoint Inhibitor in Critical Care
по: Ruiting Li, и др.
Опубликовано: (2021-06-01)

On Demand Biosensors for Early Diagnosis of Cancer and Immune Checkpoints Blockade Therapy Monitoring from Liquid Biopsy
по: Sai Mummareddy, и др.
Опубликовано: (2021-12-01)

PD-1/PD-L1 immune checkpoint inhibitors in glioblastoma: clinical studies, challenges and potential
по: Tianrui Yang, и др.
Опубликовано: (2021-02-01)

PD-L1 expression on malignant cells is no prerequisite for checkpoint therapy
по: Jan Willem Kleinovink, и др.
Опубликовано: (2017-04-01)

Epigenetic modifications of the immune-checkpoint genes CTLA4 and PDCD1 in non-small cell lung cancer results in increased expression
по: Sebastian Marwitz, и др.
Опубликовано: (2017-05-01)

Immune Checkpoint Inhibitors in Cancer Therapy
по: Yavar Shiravand, и др.
Опубликовано: (2022-04-01)

Research Progress on Cardiotoxicity of PD-1/PD-L1 Immune Checkpoint Inhibitors
по: YU Lin, и др.
Опубликовано: (2021-08-01)

The Role of Immune Checkpoint Inhibitors in Cancer Therapy
по: Ahmed M. Basudan
Опубликовано: (2022-12-01)

The role of immune checkpoint inhibitors in prostate cancer
по: Gabriel Surdacki, и др.
Опубликовано: (2019-03-01)

Editorial: The Roles of Checkpoint Inhibitors in Inflammatory Diseases
по: Andreas von Knethen, и др.
Опубликовано: (2021-10-01)

Activity and Safety of Immune Checkpoint Inhibitors in Neuroendocrine Neoplasms: A Systematic Review and Meta-Analysis
по: Alberto Bongiovanni, и др.
Опубликовано: (2021-05-01)

Predictive Biomarkers of Immune Checkpoint Inhibitors-Related Toxicities
по: Ya Xu, и др.
Опубликовано: (2020-10-01)

Structural Characterization of a Macrocyclic Peptide Modulator of the PD-1/PD-L1 Immune Checkpoint Axis
по: Edyta Zyla, и др.
Опубликовано: (2021-08-01)

The Neonatal Innate Immune Response to Sepsis: Checkpoint Proteins as Novel Mediators of This Response and as Possible Therapeutic/Diagnostic Levers
по: Emily Hensler, и др.
Опубликовано: (2022-07-01)

Key questions about the checkpoint blockade-are microRNAs an answer?
по: Mihnea Dragomir, и др.
Опубликовано: (2018-06-01)

Vascular Targeting to Increase the Efficiency of Immune Checkpoint Blockade in Cancer
по: Maria Georganaki, и др.
Опубликовано: (2018-12-01)

Enhancement of anti-tumor efficacy of immune checkpoint blockade by alpha-TEA
по: William L. Redmond, и др.
Опубликовано: (2023-02-01)

The epigenetic immunomodulator, HBI-8000, enhances the response and reverses resistance to checkpoint inhibitors
по: Reid P. Bissonnette, и др.
Опубликовано: (2021-08-01)

Advances in immune checkpoint inhibitors for hepatocellular carcinoma
по: Ji Won Han, и др.
Опубликовано: (2021-09-01)

Immune Checkpoint Inhibitors: Ctla-4 and Pd-1/Pd-l1 in Immunotherapy
по: Kübra KAHVECİ, и др.
Опубликовано: (2019-12-01)

Radiation, Immune Checkpoint Blockade and the Abscopal Effect: A Critical Review on Timing, Dose and Fractionation
по: Zachary S. Buchwald, и др.
Опубликовано: (2018-12-01)

Safety and efficacy of PD-1/PD-L1 immune checkpoint inhibitors in patients with pre-treated advanced stage malignant mesothelioma: a systematic review and meta-analysis
по: Amjad Zafar, и др.
Опубликовано: (2024-11-01)

The impact of antibiotic use on clinical features and survival outcomes of cancer patients treated with immune checkpoint inhibitors
по: Jiaxin Zhou, и др.
Опубликовано: (2022-07-01)

Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons
по: Adel Naimi, и др.
Опубликовано: (2022-04-01)

Editorial: Biomarkers of Immune-Checkpoint-Inhibitor Immunotherapies in Hepatocellular Carcinomas
по: Zhanjun Guo, и др.
Опубликовано: (2022-03-01)

Profiling targetable immune checkpoints in osteosarcoma
по: Troy A McEachron, и др.
Опубликовано: (2018-12-01)

The Use of Phytochemicals to Improve the Efficacy of Immune Checkpoint Inhibitors: Opportunities and Challenges
по: Deniz Can Guven, и др.
Опубликовано: (2022-10-01)

Commentary: Chronic PD-1 Checkpoint Blockade Does Not Affect Cognition or Promote Tau Clearance in a Tauopathy Mouse Model
по: Kuti Baruch, и др.
Опубликовано: (2020-05-01)

NSCLC: from tumorigenesis, immune checkpoint misuse to current and future targeted therapy
по: Leona Raskova Kafkova, и др.
Опубликовано: (2024-02-01)

Efficacy and safety of immune checkpoint inhibitors in non-small cell lung cancer
по: Shuai Wang, и др.
Опубликовано: (2018-08-01)

PD/1-PD-Ls Checkpoint: Insight on the Potential Role of NK Cells
по: Silvia Pesce, и др.
Опубликовано: (2019-06-01)

In Search of Better Peptide-(Derived from PD-L2)-Based Immune Checkpoint Inhibitors
по: Boris Klebansky, и др.
Опубликовано: (2024-05-01)